Cargando…

Spotlight on Lonapegsomatropin Once-Weekly Injection and Its Potential in the Treatment of Growth Hormone Deficiency in Pediatric Patients

Lonapegsomatropin, a long-acting GH therapy (LAGH), was approved by the United States Food and Drug Administration in August 2021 for the treatment of pediatric growth hormone deficiency (GHD). Lonapegsomatropin is a prodrug consisting of unmodified GH transiently conjugated to methoxypolyethylene g...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miller, Bradley S, Yuen, Kevin C J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250779/ https://www.ncbi.nlm.nih.gov/pubmed/35791404 http://dx.doi.org/10.2147/DDDT.S336285

Ejemplares similares

Average IGF-1 Prediction for Once-Weekly Lonapegsomatropin in Children With Growth Hormone Deficiency
por: Lin, Zhengning, et al.
Publicado: (2021)

Weekly Lonapegsomatropin in Treatment–Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial
por: Thornton, Paul S, et al.
Publicado: (2021)

Switching to Weekly Lonapegsomatropin from Daily Somatropin in Children with Growth Hormone Deficiency: The fliGHt Trial
por: Maniatis, Aristides K., et al.
Publicado: (2022)

Design of the ForesiGHt Trial: A Multicenter, Randomized, Placebo- and Active-Controlled Trial to Compare Once-Weekly TransCon hGH (lonapegsomatropin) to Placebo and Daily Somatropin in Adults With Growth Hormone Deficiency (GHD)
por: Fleseriu, Maria, et al.
Publicado: (2021)

Response to Letter to the Editor From Malozowski: “Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial”
por: Thornton, Paul S, et al.
Publicado: (2021)

RF26 | PMON332 Safety and Efficacy of Treatment with Lonapegsomatropin in Children with Growth Hormone Deficiency at Week 130 in the enliGHten Trial
por: Saenger, Paul, et al.
Publicado: (2022)

Safety and Efficacy of Lonapegsomatropin in Children With Growth Hormone Deficiency: enliGHten Trial 2-Year Results
por: Maniatis, Aristides K, et al.
Publicado: (2022)

Letter to the Editor From Sävendahl et al.: “Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial”
por: Sävendahl, Lars, et al.
Publicado: (2021)

Response to Letter to the Editor From L. Sävendahl et al: “Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial”
por: Thornton, Paul S, et al.
Publicado: (2021)

THU173 Subanalysis By Tanner Stage In Phase 3 Trials In Children And Adolescents With Growth Hormone Deficiency Treated With Lonapegsomatropin
por: Hofman, Paul, et al.
Publicado: (2023)

PMON329 Survey of physician experience with once weekly somatrogon vs once daily somatropin regimen for the treatment of pediatric patients with growth hormone deficiency: results from a cross sectional, observational study
por: Gomez, Roy, et al.
Publicado: (2022)

Physician experience with once-weekly somatrogon versus once-daily rhGH regimen in pediatric patients with growth hormone deficiency: a cross-sectional survey of physicians from the global phase 3 study
por: Gomez, Roy, et al.
Publicado: (2023)

Efficacy and Safety of up to 2 Years of Treatment With TransCon hGH (Lonapegsomatropin) in Treatment-Naïve and Treatment-Experienced Children With Growth Hormone Deficiency
por: Maniatis, Aristides K, et al.
Publicado: (2021)

Similar safety and efficacy in previously treated adults with growth hormone deficiency randomized to once‐weekly somapacitan or daily growth hormone
por: Otsuka, Fumio, et al.
Publicado: (2020)

Efficacy and Safety of Once-Weekly Somatrogon Compared with Once-Daily Somatropin (Genotropin®) in Japanese Children with Pediatric Growth Hormone Deficiency: Results from a Randomized Phase 3 Study
por: Horikawa, Reiko, et al.
Publicado: (2022)

Spotlight on once-monthly long-acting injectable aripiprazole and its potential as maintenance treatment for bipolar I disorder in adult patients
por: Torres-Llenza, Vanessa, et al.
Publicado: (2018)

Spotlight on grazoprevir–elbasvir once-daily combination and its potential in the treatment of hepatitis C
por: Suraweera, Duminda, et al.
Publicado: (2016)

Treatment Adherence to Injectable Treatments in Pediatric Growth Hormone Deficiency Compared With Injectable Treatments in Other Chronic Pediatric Conditions: A Systematic Literature Review
por: Gomez, Roy, et al.
Publicado: (2022)

The pharmacokinetic and pharmacodynamic properties and short-term outcome of a novel once-weekly PEGylated recombinant human growth hormone for children with growth hormone deficiency
por: Liang, Yan, et al.
Publicado: (2022)

Optimal Monitoring of Weekly IGF-I Levels During Growth Hormone Therapy With Once-Weekly Somapacitan
por: Juul Kildemoes, Rasmus, et al.
Publicado: (2020)

OR21-04 Long-term Efficacy And Safety Of Once-weekly Somatrogon In Pediatric Subjects With Growth Hormone Deficiency: Results From Up To 8 Years Of Somatrogon Treatment
por: Zadik, Zvi, et al.
Publicado: (2023)

Growth Hormone Deficiency Following Traumatic Brain Injury in Pediatric and Adolescent Patients: Presentation, Treatment, and Challenges of Transitioning from Pediatric to Adult Services
por: Wexler, Tamara L., et al.
Publicado: (2023)

SAT-LB074 Efficacy and Safety of Once-weekly Somapacitan in Adult Growth Hormone Deficiency (AGHD) Confirmed in a 53‑week Real 1 Trial Extension
por: Johannsson, Gudmundur, et al.
Publicado: (2019)

Patients' preferences for once‐daily oral versus once‐weekly injectable diabetes medications: The REVISE study
por: Boye, Kristina, et al.
Publicado: (2020)

Weekly somapacitan had no adverse effects on glucose metabolism in adults with growth hormone deficiency
por: Takahashi, Yutaka, et al.
Publicado: (2022)

Study of twice-weekly injections of Teriparatide by comparing efficacy with once-weekly injections in osteoporosis patients: the TWICE study
por: Sugimoto, T., et al.
Publicado: (2019)

OR10-05 Phase 3 FliGHt Trial: Experience of Switching from Daily Growth Hormone Therapy to Once-Weekly TransCon HGH in Children with Growth Hormone Deficiency
por: Maniatis, Aristides K, et al.
Publicado: (2020)

Role of hyaluronan in pancreatic cancer biology and therapy: Once again in the spotlight
por: Sato, Norihiro, et al.
Publicado: (2016)

Model-Based Analysis of IGF-I Response, Dosing, and Monitoring for Once-Weekly Somapacitan in Children With GH Deficiency
por: Kildemoes, Rasmus J, et al.
Publicado: (2023)

SAT-LB12 Once-Weekly Somapacitan vs Daily Growth Hormone in Growth Hormone Deficiency: 2-Year Safety Results From Real 3, a Randomized Phase 2 Trial
por: Savendahl, Lars S, et al.
Publicado: (2020)

Usefulness and Potential Pitfalls of Long-Acting Growth Hormone Analogs
por: Yuen, Kevin C. J., et al.
Publicado: (2021)

THU174 Model-Based Analysis Of IGF-I Response, Dosing, And Monitoring For Once-Weekly Somapacitan In Children With GH Deficiency
por: Kildemoes, Rasmus Juul, et al.
Publicado: (2023)

Growth hormone deficiency, acromegaly and COVID-19: Transitioning from media reports to knowledge and a growth hormone hypothesis
por: Yuen, Kevin C.J.
Publicado: (2021)

RF26 | PSAT150 Growth Outcomes From the Phase 2 and Phase 3 Studies of Once Weekly Somatrogon vs Daily Genotropin in Pediatric Patients With Growth Hormone Deficiency: Comparisons With Published Literature and an International Growth Study Database
por: Cara, Jose, et al.
Publicado: (2022)

SAT-LB15 24-Month Efficacy and Safety of Once Weekly and Every Other Week Administration of GX-H9, Hybrid FC-Fused Long-Acting Human Growth Hormone: A Phase 2 Study in Children With Growth Hormone Deficiency
por: Malievskiy, Oleg, et al.
Publicado: (2020)

Corrigendum: Usefulness and Potential Pitfalls of Long-Acting Growth Hormone Analogues
por: Yuen, Kevin C. J., et al.
Publicado: (2021)

Growth hormone replacement therapy in adults with growth hormone deficiency; thrice weekly low dose administration.
por: Chung, Y. S., et al.
Publicado: (1994)

Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial
por: Johannsson, Gudmundur, et al.
Publicado: (2018)

Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany
por: Qiao, Qing, et al.
Publicado: (2016)

Efficacy of once-weekly and twice-weekly injections of teriparatide by patient characteristics: A post hoc analysis of the TWICE study
por: Sugimoto, Toshitsugu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_r3bk35c34204ucp7rge2a19842